Economic evaluation of human papillomavirus vaccination in the United Kingdom.
about
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesHuman papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active women7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?Targeting vaccination against novel infections: risk, age and spatial structure for pandemic influenza in Great BritainSchool nurses' experiences of delivering the UK HPV vaccination programme in its first yearModeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Epidemiology and costs of cervical cancer screening and cervical dysplasia in ItalyEstimating progression rates for human papillomavirus infection from epidemiological data.Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men.Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005-2008).Explaining variation in the uptake of HPV vaccination in England.Cost-effectiveness of different human papillomavirus vaccines in SingaporeCost-effectiveness analysis of the nine-valent HPV vaccine in Italy.Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England.Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical modelsEfficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policiesThe role of mathematical modelling in guiding the science and economics of malaria eliminationAcceptability and correlates of primary and secondary prevention of cervical cancer among medical students in southwest China: implications for cancer education.Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study.Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?Towards the eradication of HPV infection through universal specific vaccination.Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission modelVaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.Combating pertussis resurgence: One booster vaccination schedule does not fit allRevisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females.Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran.Next Generation Cancer Protection: The Bivalent HPV Vaccine for FemalesDirect benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesisHigh-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey.Genital warts and cost of care in EnglandThe impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UKHuman papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies.Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain.Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in ChinaThe economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach.
P2860
Q24655328-F67A957C-8411-4C42-8884-510BAB450123Q26824062-41AFC73B-33C4-4171-8C51-49E10576C6A7Q28743870-500ED4CA-150C-4E68-A133-B4B580F513A7Q30394832-F070002A-D682-4BD0-8828-40A39F86F952Q30504491-9977CCC3-58EC-441F-8506-55B470E1AB63Q30573204-3FBBB19E-E52D-4DB4-A7CA-21641AF0B162Q33412571-F80D5C72-7077-400A-8F03-73E9E6525171Q33467330-CAA18041-949D-41DD-AD20-895DFEB956EBQ33523171-305E8519-499C-412A-860B-396A31A51F3EQ33602635-95BA3EF4-044F-4695-AB80-E4869F8F330EQ33716762-8609378B-448F-4717-9EF9-3F75347EBAECQ33852578-ECB36013-9046-481C-B148-3442F431FB24Q33859018-E937F6DA-56C9-4D8A-8C95-8CC59B676677Q33892348-BC1947B5-5298-4008-B987-334A19A7DAADQ34005902-F8A4741C-9873-4823-B635-0BAA72463272Q34113476-393A61B3-FAB5-47BA-9569-0E44DE7D8CF3Q34199773-B012E5F5-DC77-4BE0-972F-8070D572503DQ34415327-4C999B4F-8341-4D4F-9F84-C435F7880FDCQ34434281-993F6F4E-F541-4499-90AB-2BB3E850F19FQ34462627-F71AB947-A70B-45FE-8092-49DA84F01FD2Q34580293-B482840C-77A2-469D-A268-689EF1A1AF31Q34806423-B737D90E-AAE4-4E6A-93C3-1E5391F2F6A3Q34812959-121C57EC-A73F-4397-835A-6B8C9505E169Q34852567-149AA356-BA5F-42F8-8221-44CB7A984B7CQ35005743-4289ACEF-A67A-473B-82C9-4746B957129BQ35062572-A57BE3F0-5B8F-4BA3-9C03-F03FC21C3285Q35092114-B75EFCE5-B0A7-4AA9-93FD-069A53AB7CCEQ35126586-DF1E9F08-7363-4525-8874-78006A71AAB5Q35127307-46793555-B0C6-4BA2-9C95-B821CCC3F266Q35235306-32B2235C-2E8F-4757-AEB8-1C7685E0C30DQ35484171-CFE5D790-2CC5-46AA-9575-E5E52C73DF8DQ35550810-176AA2C9-B887-464E-800B-1C33F26B7C63Q35596183-8F044152-22A2-4417-986B-1BFD72E3D631Q35619059-B3801F6C-956E-40AB-950E-D72B3C208C81Q35658387-AFB322C9-7EC7-4980-AFE0-4BB5C4B51714Q35658392-F7C45B70-5019-4031-92F4-C567616AE6E0Q35677956-FD566B09-FFF6-4981-99A3-2AE00EAF9157Q35841460-0D67EA76-09AB-4C51-BDEC-629F112197DEQ35937679-9E8DB5D9-C316-4DA5-9F9C-EE8C07F35F8AQ36109733-88A979A9-386C-49AC-8F69-C8150F9879A9
P2860
Economic evaluation of human papillomavirus vaccination in the United Kingdom.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Economic evaluation of human papillomavirus vaccination in the United Kingdom.
@ast
Economic evaluation of human papillomavirus vaccination in the United Kingdom.
@en
type
label
Economic evaluation of human papillomavirus vaccination in the United Kingdom.
@ast
Economic evaluation of human papillomavirus vaccination in the United Kingdom.
@en
prefLabel
Economic evaluation of human papillomavirus vaccination in the United Kingdom.
@ast
Economic evaluation of human papillomavirus vaccination in the United Kingdom.
@en
P2860
P356
P1433
P1476
Economic evaluation of human papillomavirus vaccination in the United Kingdom.
@en
P2093
Yoon Hong Choi
P2860
P356
10.1136/BMJ.A769
P407
P577
2008-07-17T00:00:00Z